Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNA028 in Advanced Colorectal Cancer
NCT07590856Phase 1Not yet recruiting
- Sponsor
- SmartNuclide
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label trial of SNA028 in colorectal cancer (CRC) (7 arms), sponsored by SmartNuclide. Primary endpoints: Safety and Tolerability of SNA028 at 3 weeks, Pharmacokinetics of the GPA33-CC protein up to 1 week and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
SNA028
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07590856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07590856.